NLRP3-IN-51

Product Specifications

UNSPSC Description

NLRP3-IN-51 (Compound 3q) is a potent cholinergic anti-inflammatory pathway (CAP) activators. ANLRP3-IN-51 inhibits Monosodium urate (MSU) (HY-B2130A)-induced IL-1β production in THP-1 cells, indicating its potential against gout arthritis. NLRP3-IN-51 inhibits MSU induced phosphorylation of NF-κB p65, without any inhibitory effect against NLRP3, pro-caspase 1, or the self-cleavage and activation of caspase-1 of the second signaling. Therefore, NLRP3-IN-51 inhibits the initial phase of NLRP3 through CAP activation[1].

Target Antigen

NF-κB

Type

Reference compound

Related Pathways

NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/anti-inflammatory-agent-93.html

Smiles

CC1=CC(C)=CC(C)=C1OC2=NC(C[C@H]3[C@](C=C)([H])[C@]4(N(C)C)CC(C)=C3)=C4C=C2

Molecular Weight

388.55

References & Citations

[1]Wu HR, et al. Identification of O-arylated huperzinines as novel cholinergic anti-inflammatory pathway agonists against gout arthritis. Bioorg Chem. 2024 Nov;152:107716.